ArticleCommunications biology2025
O-glycosylated peptides curtail the aggregation and toxicity of human islet amyloid polypeptide.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Functional Engineering of Bioactive Peptides: Chemical Modifications and Synthetic Biology Approaches.International journal of molecular sciences · 2026Review
- Caveolin-1 Modulates Islet Amyloid Polypeptide Expression Through Interaction with TXNIP in Murine Pancreatic β-Cells.Biomedicines · 2026Article
- Anthraquinones Inhibit Insulin Amyloidosis in Crowded Environments.Molecules (Basel, Switzerland) · 2026Article
- Molecular Mechanisms of Islet Amyloid Polypeptide Aggregation: Towards Chemical Strategies to Prevent Amyloid Formation and to Design Non-Aggregating Peptide Therapeutics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A key pathogenetic pathway of type 2 diabetes (T2D) is pancreatic beta cell failure, losing their capability of producing insulin and regulating blood glucose. Accumulated evidence has demonstrated that the elevated aggregations of human islet amyloid polypeptide (hIAPP), consisting of soluble oligomers and insoluble fibrils, contribute to the beta cell dysfunction and loss. In this work, a focused library of O-glycosylated peptides was designed to target hIAPP monomers. An N-acetylglucosamine modified peptide, S
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.